Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Other Non-Current Liabilities (2023)

Tonix Pharmaceuticals Holding has reported Other Non-Current Liabilities over the past 1 years, most recently at $14.6 million for Q4 2023.

  • Quarterly results put Other Non-Current Liabilities at $14.6 million for Q4 2023, changed N/A from a year ago — trailing twelve months through Dec 2023 was $14.6 million (changed N/A YoY), and the annual figure for FY2023 was $14.6 million, changed.
  • Other Non-Current Liabilities for Q4 2023 was $14.6 million at Tonix Pharmaceuticals Holding.
  • Over the last five years, Other Non-Current Liabilities for TNXP hit a ceiling of $14.6 million in Q4 2023 and a floor of $14.6 million in Q4 2023.